Transmission of fluconazole-resistant Candida albicans between patients with AIDS and oropharyngeal candidiasis documented by pulsed-field gel electrophoresis.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Transmission of fluconazole-resistant Candida albicans between patients with AIDS and oropharyngeal candidiasis documented by pulsed-field gel electrophoresis.

Clin Infect Dis. 1995 Sep;21(3):561-4. Unique Identifier : AIDSLINE MED/96077374
Barchiesi F; Hollis RJ; Del Poeta M; McGough DA; Scalise G; Rinaldi MG; Pfaller MA; Department of Pathology, University of Texas Health Science; Center, San Antonio 78284-7750, USA.

Abstract: Electrophoretic karyotype and restriction endonuclease analysis of genomic DNA were used for the typing of nine isolates of Candida albicans from the oral cavities of two patients with AIDS--a husband and wife--whose infections became resistant to treatment with fluconazole (400 mg/d). The in vitro susceptibilities of sequential isolates to fluconazole and two other triazoles, itraconazole and the investigational drug D0870, were also evaluated. DNA analysis showed that the isolates responsible for fluconazole-resistant episodes of oropharyngeal candidiasis in the two patients were genetically related. In vitro susceptibility to fluconazole correlated well with clinical outcome. Although the minimal inhibitory concentrations of itraconazole and D0870 for fluconazole-resistant isolates were higher than those for fluconazole-susceptible isolates, both of the former triazoles exhibited good in vitro activity against the isolates tested.

Keywords: Adult AIDS-Related Opportunistic Infections/DRUG THERAPY/MICROBIOLOGY/ *TRANSMISSION Candida albicans/DRUG EFFECTS/GENETICS/ISOLATION & PURIF Candidiasis, Oral/*COMPLICATIONS/DRUG THERAPY/*TRANSMISSION Case Report Drug Resistance, Microbial DNA, Fungal/GENETICS/ISOLATION & PURIF Electrophoresis, Gel, Pulsed-Field Female Fluconazole/PHARMACOLOGY Human Male Pharyngeal Diseases/*COMPLICATIONS/DRUG THERAPY/MICROBIOLOGY Support, Non-U.S. Gov't JOURNAL ARTICLE
960430
M9640834

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .